Version 1
: Received: 17 December 2020 / Approved: 21 December 2020 / Online: 21 December 2020 (10:26:54 CET)
Version 2
: Received: 23 December 2020 / Approved: 24 December 2020 / Online: 24 December 2020 (13:51:51 CET)
Igyártó, B. Z.; Jacobsen, S.; Ndeupen, S. Future Considerations for the mRNA-Lipid Nanoparticle Vaccine Platform. Current Opinion in Virology, 2021, 48, 65–72. https://doi.org/10.1016/j.coviro.2021.03.008.
Igyártó, B. Z.; Jacobsen, S.; Ndeupen, S. Future Considerations for the mRNA-Lipid Nanoparticle Vaccine Platform. Current Opinion in Virology, 2021, 48, 65–72. https://doi.org/10.1016/j.coviro.2021.03.008.
Igyártó, B. Z.; Jacobsen, S.; Ndeupen, S. Future Considerations for the mRNA-Lipid Nanoparticle Vaccine Platform. Current Opinion in Virology, 2021, 48, 65–72. https://doi.org/10.1016/j.coviro.2021.03.008.
Igyártó, B. Z.; Jacobsen, S.; Ndeupen, S. Future Considerations for the mRNA-Lipid Nanoparticle Vaccine Platform. Current Opinion in Virology, 2021, 48, 65–72. https://doi.org/10.1016/j.coviro.2021.03.008.
Abstract
Vaccines based on mRNA-containing lipid nanoparticles (LNPs) pioneered by Katalin Karikó and Drew Weissman at the University of Pennsylvania are a promising new vaccine platform used by two of the leading vaccine candidates against coronavirus disease in 2019 (COVID-19). However, there are many questions regarding their mechanism of action in humans that remain unanswered. Here we consider the immunological features of LNP components and off-target effects of the mRNA, both of which could increase the risk of side effects. We suggest ways to mitigate these potential risks by harnessing dendritic cell (DC) biology.
Keywords
mRNA-LNP vaccines; side effects; dendritic cells
Subject
Biology and Life Sciences, Immunology and Microbiology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Commenter: Botond Igyártó
Commenter's Conflict of Interests: Author